Blanca AndinoPhD Student, Icahn School of Medicine at Mount Sinai
Blanca Andino graduated in 2007 with a BA in Biology from Hunter College of The City University of New York. She pursued her interests in biomedical research in the laboratory of Dr. Ben Ortiz at Hunter College, where she studied gene regulation during T-cell development from 2004 until 2009. In the fall of 2009, Blanca joined the PhD program at the Icahn School of Medicine at Mount Sinai where she is currently studying various aspects of chromatin biology in the laboratory of Dr. Martin Walsh.
Michael BierutPartner, Pentagram New York
Michael Bierut joined Pentagram as a partner in 1990. Prior to that, he was vice president of graphic design at Vignelli Associates. His clients at Pentagram have included the New York Jets, The New York Times, The Museum of Arts and Design, United Airlines, The Brooklyn Academy of Music, Yale University, the Morgan Library and Museum, and Saks Fifth Avenue.
He has won hundreds of design awards and his work is represented in the permanent collections of museums around the world. He has served as president of the New York Chapter of the American Institute of Graphic Arts (AIGA) and as that organization's national president. For the last ten years he has been a Senior Critic in the graphic design program at the Yale School of Art, and a senior faculty fellow at the Yale School of Management. In 2002, Michael Bierut co-founded Design Observer, a blog that is the largest design publication in the world. In 2008, he was named winner in the Design Mind category of the Cooper-Hewitt National Design Awards.
Dennis S. Charney, MDAnne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai President for Academic Affairs, Mount Sinai Health System
Dennis S. Charney, MD, is Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. He is also a world expert in the neurobiology and treatment of mood and anxiety disorders, making fundamental contributions to the understanding of the causes of human anxiety, fear, and depression and the discovery of new treatment for mood and anxiety disorders.
Since Dr. Charney was named Dean in 2004, the Icahn School of Medicine has risen to, and has maintained, its strength among the top 20 institutions in National Institutes of Health (NIH) funding. It currently ranks fifth in funding per faculty member from the NIH and other sources. With a long track record of strategic recruitments across the biomedical sciences and in genomics, computational biology, entrepreneurship, and information technology, Mount Sinai has cultivated a supercharged, Silicon Valley-like atmosphere in the academic setting. ISMMS The Icahn School of Medicine is also consistently listed among the top 20 medical schools in the country according to U.S. News & World Report, and in 2009, it received the Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
As the sole medical school affiliation for seven hospital campuses in the new Mount Sinai Health System, the Icahn School of Medicine has one of the most expansive training and research footprints in the nation. Early in his tenure as Dean, Dr. Charney unveiled Mount Sinai's $2.25 billion strategic plan that laid the foundation for the 14 robust Research Institutes that Mount Sinai is known for today. These institutes are hubs of scientific and clinical enterprise, working together to challenge the limits of science and medicine. Within-and across-them, scientists and physicians, who themselves are members of the teaching faculty, can facilitate the development of effective treatments for the most serious medical conditions.
In the Health System, Dr. Charney is currently developing the structure for complementary Clinical Institutes that will serve as Centers of Excellence for cancer, heart disease, diabetes, HIV, pulmonary diseases, and more, with the anticipation that this architecture-compatible research and clinical institutes-will further eliminate silos and generate game-changing models in clinical excellence and standards of care. To further advance this goal, Dr. Charney also led the development of a nationally unique partnership between Mount Sinai and Rensselaer Polytechnic Institute in Troy, New York, that is designed to pool Mount Sinai's expertise in biomedical research and patient care with Rensselaer's talent in engineering, computation, and prototyping. Together, the institutions are developing the educational programs, research projects, and infrastructure needed to invent novel biomedical technologies while training a new breed of translationally focused scientists.
Dr. Charney's career began in 1981 at Yale, where, within nine years, he rose from Assistant Professor to Professor of Psychiatry, a position he held from 1990 to 2000. While there, he chaired the National Institute of Mental Health (NIMH) Board of Scientific Counselors, which advises the institute's director on intramural research programs. In 2000, NIMH recruited Dr. Charney to lead the Mood and Anxiety Disorder Research Program-one of the largest programs of its kind in the world-and the Experimental Therapeutics and Pathophysiology Branch. That year, he was also elected to the Institute of Medicine of the National Academy of Sciences. His scientific research has been honored by every major award in his field, and his work in depression has led to new hypotheses regarding the mechanisms of antidepressant drugs and discovery of new and novel therapies for treatment-resistant depression, including lithium and ketamine. The work demonstrating that ketamine is a rapidly acting antidepressant has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. More recently, his pioneering research has expanded to include the psychobiological mechanisms of human resilience to stress.
Dr. Charney's studies on human resilience have culminated in the identification of ten key resilience factors for building the strength to weather and bounce back from stress and trauma. This work is summarized in an inspiring book, Resilience: The Science of Mastering Life's Greatest Challenges, coauthored with Steven Southwick and published by Cambridge University Press in 2012.
In 2004, the Icahn School of Medicine at Mount Sinai recruited Dr. Charney as Dean of Research. In 2007, he became the Dean of the School and Executive Vice President for Academic Affairs of the Medical Center. In 2013, he was named President for Academic Affairs for the Health System.
A prolific author, Dr. Charney has written more than 700 publications, including groundbreaking scientific papers, chapters, and books. He has authored many books, including Neurobiology of Mental Illness (Oxford University Press, USA, Fourth Edition, 2013); The Peace of Mind Prescription: An Authoritative Guide to Finding the Most Effective Treatment for Anxiety and Depression (Houghton Mifflin Harcourt, 2004); The Physicians Guide to Depression and Bipolar Disorders (McGraw-Hill Professional, 2006), Resilience and Mental Health: Challenges Across the Lifespan (Cambridge University Press, 2011), and, as mentioned, Resilience: The Science of Mastering Life's Greatest Challenges, for lay audiences (Cambridge University Press, 2012).
Noshir Contractor, PhDJane S. and William J. White Professor of Behavioral Sciences Director of the Science of Networks in Communities (SONIC) Research Group Northwestern University
Noshir Contractor, PhD, is the Jane S. and William J. White Professor of Behavioral Sciences at Northwestern University. He is also the Director of the Science of Networks in Communities (SONIC) Research Group at Northwestern University. He is investigating factors that lead to the formation, maintenance, and dissolution of dynamically linked social and knowledge networks. His research program has been funded continuously for over a decade by major grants from the National Science Foundation, as well as other agencies including the Army Research Laboratory and the MacArthur Foundation.
His book titled Theories of Communication Networks (co-authored with Professor Peter Monge and published by Oxford University Press) received the 2003 Book of the Year award from the Organizational Communication Division of the National Communication Association. Professor Contractor is the co-founder and Chairman of Syndio Social, which offers organizations products and services based on network analytics.
Michael M. Crow, PhDPresident, Arizona State University
Michael M. Crow became the sixteenth president of Arizona State University in 2002. Dr. Crow is guiding the transformation of ASU into one of the nation's leading public metropolitan research universities, an institution combining academic excellence, inclusiveness, and societal impact - a model he terms the "New American University." During his tenure, ASU has established major transdisciplinary research initiatives and witnessed an unprecedented academic infrastructure expansion, tripling of research expenditures, and attainment of record levels of diversity. He was previously executive vice provost of Columbia University. A fellow of the American Association for the Advancement of Science (AAAS) and National Academy of Public Administration, he is the author of books and articles analyzing knowledge enterprises and science and technology policy.
Kenneth L. Davis, MDPresident and Chief Executive Officer, Mount Sinai Health System Professor of Psychiatry, Icahn School of Medicine at Mount Sinai
Kenneth L. Davis, MD, was named President and CEO of the Mount Sinai Health System in September 2013. For the decade prior to that, he served as President and CEO of The Mount Sinai Medical Center and during his tenure, he and Peter W. May, Chairman of the Boards of Trustees, launched one of the largest financial turnarounds in academic medicine. The Medical Center grew in both scope and ambition, entering a new era of innovation in collaborative research, education, and clinical care.
Dr. Davis received his bachelor's degree from Yale College, from which he graduated magna cum laude and phi beta kappa. He received his medical degree from Mount Sinai School of Medicine and was valedictorian. He completed an internship, residency, and fellowship in psychiatry, and pharmacology, respectively, at Stanford University Medical Center, and thereafter won a career development award from the Veterans Administration to pursue his research in cholinergic mechanisms and neuropsychiatric diseases.
In 1979, Dr. Davis joined the faculty at Mount Sinai, becoming Chief of Psychiatry at the Bronx Veterans Administration (VA) Medical Center. He spearheaded Mount Sinai's research program in the biology of schizophrenia and the therapeutics of Alzheimer's disease and directed Mount Sinai's National Institute on Aging (NIA)-supported Alzheimer?s Disease (AD) Research Center from 1984 through 2002. His work focused on all aspects of experimental therapeutics, including animal models, assessment instruments, and design issues in drug testing. As early as 1978, he first suggested that cholinomimetic therapy could be useful for the treatment of AD, and shortly thereafter conducted the first positive proof of concept study with cholinesterase inhibitors in this disease. Subsequently, he coordinated the first multicenter NIA-funded trial of tacrine. This groundbreaking work eventually led to the discovery, development, and approval of the drugs used for AD today. In 1987, he was appointed Chairman of Psychiatry, Mount Sinai School of Medicine.
Dr. Davis also directed the NIMH funded Silvio O. Conte Center for the Neurosciences of Mental Disorders. This multimillion-dollar Center focuses on schizophrenia and is based on the premise that white matter, oligodendrocytes and myelin may be compromised in schizophrenia. It has opened an entirely new approach to this devastating disease. Over the course of his career, he has received tens of millions of dollars of NIH grants to study major brain diseases.
The author or co-author of more than 575 scientific articles, Dr. Davis has been recognized by ISI as one of the most highly cited researchers in the field of brain diseases. Dr. Davis is a member of the editorial boards of numerous journals, and has won virtually every major research award in psychiatric research from the major societies in this field.
He has had the privilege of serving terms as President to the Society of Biological Psychiatry and the American College of Neuropsychopharmacology, as well as Chairman of the Board for the Greater New York Hospital Association, and the League of Voluntary Hospitals & Homes of New York.
In addition to his election to membership in the Institute of Medicine (IOM) of the National Academy of Sciences, among his many other honors are the George H.W. Bush '48 Lifetime of Leadership Award—a distinction given to Yale alumni athletes who make significant breakthroughs in their professions, the Rita Hayworth Award from the Alzheimer?s Association, the Kempf Fund Award for Research Development in Psychobiological Psychiatry from the American Psychiatric Association, the Gold Medal Award from the Society of Biological Psychiatry for Outstanding Achievement in Psychobiological Research, the American Psychiatric Association Award for Research in Psychiatry, the Joel Elkes International Award given by ACNP for outstanding research in neuropsycho-pharmacology, and numerous others.
In January 2003, he was appointed Dean of Mount Sinai School of Medicine, as it was then called, and in March 2003 he assumed the additional position of President and Chief Executive Officer of The Mount Sinai Medical Center. In 2007, Dr. Davis named a new Dean for the School of Medicine.
When Dr. Davis was named President and CEO, Mount Sinai was threatened with bankruptcy and the cash account was barely adequate to make payroll. The plan he developed focused on growth rather than cost reduction, contradicting the path offered by the consultants who were advising Mount Sinai at that time. The Boards of Trustees of Mount Sinai endorsed Dr. Davis's plan. Today, Mount Sinai has an A-category status from all bond-rating agencies and for the past three years, the Hospital has ranked among the top 15 in the country. The School of Medicine, which had previously ranked in mid-40s nationally, quickly accelerated in the rankings to reach the top 20.
Building on these achievements, Dr. Davis led a philanthropic campaign that reached its goal of $1.6 billion, fueled a nearly $200 million gift from Carl C. Icahn, a longtime supporter and Trustee, which renamed the School: Icahn School of Medicine at Mount Sinai.
Given these achievements, Senate and House members and staffers call upon Dr. Davis to advise on health care matters, and print and television journalists invite him to discuss issues and advancements in science and medicine. His prominence in this areas of science, medicine and health care reform were showcased at the 2013 Aspen Ideas Festival in three sessions including a panel entitled "Can We Afford Our Health?" together with Peter Orszag, PhD, former Director of the U.S. Office of Management and Budget under President Barack Obama, and Robert Rubin, former U.S. Secretary of the Treasury under President Bill Clinton.
The success of The Mount Sinai Medical Center served as the fundamental basis for Mount Sinai's recent combination with Continuum Health Partners, resulting in the creation of the new Mount Sinai Health System. This new entity is one of the largest nonprofit systems in the country with $7 billion in revenue; 36,000 employees; seven hospital campuses; and an extensive ambulatory platform.
Laura Demopoulos, MDExecutive Director, Discovery Medicine, GlaxoSmithKline
Laura Demopoulos, MD, is a graduate of the Massachusetts Institute of Technology and NYU School of Medicine. She completed a medical internship and residency at NYU and served as Chief Resident. Her fellowship in non-interventional cardiology was also at NYU. Since then she has held academic positions at Albert Einstein Medical Center in New York and at the University of Pennsylvania. She has also worked extensively in the pharmaceutical industry, holding a variety of positions, including late-phase drug development at Merck, drug safety/pharmacovigilance at Wyeth, and early phase drug development at GlaxoSmithKline (GSK). Her research interests include: heart failure, vascular disease, thrombosis, and ischemic complications of cardiothoracic surgery. In all of these roles, optimizing team dynamics has been of critical importance.
Sara Diamond, PhDPresident and Vice-Chancellor, OCAD University
Dr. Sara Diamond is the President of OCAD University, Canada's "university of the imagination." Dr. Diamond holds a PhD in Computing, Information Technology and Engineering from the University of East London, a Masters in Digital Media theory from the University of Arts London and Honours Bachelors of Arts in History and Communications from Simon Fraser University. She is an appointee of the Order of Ontario and the Royal Canadian Society of Artists and a recipient of the Queen's Diamond Jubilee Medal. While retaining OCAD University's traditional strengths in art and design, Dr. Diamond has guided the university in becoming a leader in digital media, design research and curriculum through the Digital Futures Initiative, new research in Inclusive Design, health and design, as well as in sustainable technologies and design.
She is a data visualization, wearable technology and mobile media researcher, artist and designer. She developed www.codezebra.net, a social media software and performance and responsive fashion environment.
Her artwork is held by prestigious collections such as the Museum of Modern Art, NYC and the National Gallery of Canada.
Jonathan S. Dordick, PhDVice President for Research and the Howard P. Isermann Professor of Chemical and Biological Engineering at Rensselaer Polytechnic Institute
Jonathan S. Dordick is the Vice President for Research and the Howard P. Isermann Professor of Chemical and Biological Engineering at Rensselaer Polytechnic Institute. Dr. Dordick received his B.A. degree in Biochemistry and Chemistry from Brandeis University and his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. He has held chemical engineering faculty appointments at the University of Iowa (1987-1998), where he also served as the Associate Director of the Center for Biocatalysis and Bioprocessing, and Rensselaer Polytechnic Institute (1998-present) where he also holds joint appointments in the departments of Biomedical Engineering, Materials Science and Engineering, and Biology. Dr. Dordick's research group includes chemical engineers, bioengineers, materials scientists, biologists, chemists and microbiologists all focused on gaining a quantitative understanding of biological principles and applying them to advance bioengineering, nanobiotechnology, drug discovery, and biomanufacturing. Specific areas of current research include enzyme structure and function at biological-material interfaces, high-throughput drug and functional materials discovery, and biologically-inspired nanocomposites for 2D and 3D functional architectures.
Dr. Dordick has received numerous awards and presently serves on the Scientific Advisory Boards for several biotechnology companies and venture capital firms, and has cofounded a number of companies, including EnzyMed (now part of Albany Molecular Research, Inc.), Solidus Biosciences, and The Paper Battery Company. He has published over 300 papers and is an inventor/co-inventor on nearly 40 patents and patent applications.
Gordon EdelsteinArtistic Director, Long Wharf Theatre
Gordon Edelstein has directed over a hundred plays, musicals, and operas across the United States as well as Europe. His NYC production of "My Name Is Asher Lev" recently won the Outer Critics Circle Award for Outstanding New Off-Broadway Play. His acclaimed Long Wharf Theatre production of "The Glass Menagerie" played the Roundabout Theatre Company and the Mark Taper Forum and was the recipient of the Lucille Lortel Award for Best Revival. Other NY work includes: "The Road to Mecca," "A Skull in Connemara," "The Homecoming," "Some Americans Abroad," "BFE," and many others. He is entering his twelfth season as Artistic Director of Long Wharf Theatre (New Haven, CT), where he has begun an association with Athol Fugard, directing the premieres of his most recent work: "Coming Home," "Have You Seen Us?," "The Train Driver," and the upcoming "The Shadow of The Hummingbird" (also starring Fugard). His directing work at Long Wharf has been recognized by six Connecticut Critics Circle Awards, as well as the Tom Killen Award for extraordinary contributions to Connecticut's Equity professional theater.
Scott L. Friedman, MDDean for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai
Scott L. Friedman, MD, is founding Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai. He performed pioneering research that isolated and characterized the hepatic stellate cell, the key cell type responsible for scar production in liver. This achievement spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. In this capacity, Dr. Friedman interacts widely with the Biotech and Pharmaceutical industries in drug discovery and development, and clinical trial design. Dr. Friedman's work has been continuously funded by the National Institutes of Health since 1985; he has held many national leadership positions including President of the American Association for the Study of Liver Diseases, Senior Fulbright Fellow at the Weizmann Institute of Science, and Senior Advisory Council for the National Institute of Alcohol Abuse and Alcoholism. He has published over 250 scientific articles, and is among the most preeminent scholars in his field worldwide.
Stephen H. Friend, MD, PhDPresident, Sage Bionetworks
Stephen H. Friend is the President of Sage Bionetworks, a non-profit organization dedicated to redefining biomedical research through open systems, incentives and norms. He is an authority in the field of cancer biology and a pioneer in the field of the genetics of gene expression integrating system biology approaches to complex diseases. Under his leadership, Sage Bionetworks develops technology platforms for data-intensive analysis, governance platforms for data sharing and reuse, runs challenges to solve complex biomedical problems and performs cutting edge computational biology and research. Previously, Dr. Friend was Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck's Basic Cancer Research efforts. Formerly Dr. Friend along with Dr. Hartwell founded and co-led the Fred Hutchinson Cancer Research Center's "Seattle Project," an advanced institute for drug discovery. Later they co-founded Rosetta Inpharmatics with Dr. Leroy Hood. Dr. Friend also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his MD/PhD from Indiana University.
Annetine Gelijns, PhDChair of the Department of Health Evidence and Policy and Co-Director of the International Center for Health Outcomes and Innovation Research (InCHOIR) at The Mount Sinai Medical Center
An expert in health policy and clinical evaluative research, Annetine Gelijns' cutting-edge research has provided critical insight into the forces that drive the rate and direction of technological change in medicine that promises to improve patient outcomes and reduce health care costs.
As Chair of the Department of Health Evidence and Policy and Co-Director of the International Center for Health Outcomes and Innovation Research (InCHOIR) at Mount Sinai, Dr. Gelijns' research focuses on surgical and device-based trials; comparative effectiveness research; and the factors shaping the development and diffusion of medical technology, and their policy implications. She has written extensively about the uncertainty involved in medical research, the roles of the public and private sectors in technological change, and the dynamics of medical innovation. Her more recent work has focused on the design, execution and policy implications of clinical trials of novel surgical procedures, biologicals and devices. She directed the data coordinating center (DCC) for several NIH- and industry-supported trials as well as the DCC for the NIH- and CIHR-funded Cardiothoracic Surgical Trials Network.
Dr. Gelijns served as a consultant to various national and international organizations, including the WHO, the OECD, Paris, France, the National Academy of Engineering and the Institute of Medicine, and she was a member of the board of the International Society on Technology Assessment in Health Care. She has also authored or co-authored more than 130 peer-reviewed articles, books, book chapters, editorials and reviews.
Jon GertnerAuthor, "The Idea Factory"
Jon Gertner is Editor-at-Large at Fast Company magazine, where he writes and edits features on innovation and technology. Between 2004 and 2011, he worked at The New York Times Magazine, where he wrote about science, business, society, and economics. He has also served as a senior editor for Money and The American Lawyer. In March 2012 Penguin Press published his first book, "The Idea Factory: Bell Labs and the Great Age of American Innovation." A graduate of Cornell University, Gertner lives in New Jersey with his wife and their two children.
Michael Goldblatt, PhD, JDPresident and CEO, Functional Genetics, Inc.
Michael Goldblatt has been CEO of Functional Genetics since 2003. From 1999 to 2003, Dr. Goldblatt served as Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA) creating new materials and mathematics technologies for national security and laying the foundation to make biological research a future historical strength of the Department of Defense. Prior to his work with the Department of Defense, Michael spent 12 years with McDonald's Corporation as the Science and Technology Officer with broad global responsibilities in the areas of nutrition, product development, food safety, and corporate venture capital. Prior to McDonald's in his capacity with General Foods, he led research efforts in the use of nutrients for pharmaceutical effects and oversaw a variety of regulatory and legal issues. Dr. Goldblatt currently serves as an advisor to various government agencies, on the Boards of two journals and four emerging technology companies and maintains his legal license in Washington, DC and New York. He received his PhD and JD from University of California, Davis.
Marylens HernandezPhD Candidate, Icahn School of Medicine at Mount Sinai
Marylens Hernandez is a PhD candidate at the Icahn School of Medicine at Mount Sinai. She is currently investigating the molecular mechanisms underlying nuclear structural changes during oligodendrocyte differentiation, under the supervision of Dr. Patrizia Casaccia. Her research interests span from human genetics to neuroscience, as well as bioinformatic applications relevant to translational medicine. Her future goal is to integrate tools from different fields in order to treat diseases and promote well-being.
Paul HoldengräberDirector of LIVE from the NYPL, The New York Public Library
Known for probing his guests to step far beyond talking points and orchestrating unexpected onstage pairings, Paul Holdengräber is the director of LIVE from the NYPL and is responsible for curating the series' Spring and Fall programs each year. He has interviewed a few people in the medical world such as Atul Gawande, Oliver Sacks, Siddhartha Mukherjee, and Eric Kandel. Prior to joining The New York Public Library in 2004, Holdengräber founded and served as the director of the Institute for Art and Cultures at the Los Angeles County Museum of Art (LACMA). In 2003, the French government awarded him the Chevalier des Arts et des Lettres in recognition of his cultural contributions. He holds a Bachelor's Degree from the Universite Catholique de Louvain in Belgium and a Ph.D. in Comparative Literature from Princeton University. He was awarded a postdoctoral fellowship at the Getty Research Institute from 1995 to 1996, before starting at LACMA the following year. He has taught at Princeton University, Williams College, the University of Miami, and Claremont Graduate University. He has been a Fellow at the Los Angeles Institute for the Humanities (University of Southern California) and served as a Board Member at the Santa Monica Museum of Art from 2000 to 2004. He currently serves on the Board of Directors for the Sun Valley Writers Conference in Sun Valley, Idaho. Fluent in four languages, Holdengräber lives in Brooklyn with his wife and two sons.
Anja König, PhDManaging Director, Novartis Venture Fund
Anja König is a Managing Director of the Novartis Venture Fund. Dr. König is active in Europe and the US East Coast. Prior to joining Novartis, she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with companies in health care in the US, Europe and emerging markets. Dr. König is a scientist by training and holds a PhD in physics from Cornell University. She serves on the boards of Bicycle, Covagen, Heptares, F2G, and Nabriva.
Patricia KovatchAssociate Dean for Scientific Computing at the Icahn School of Medicine at Mount Sinai
Patricia Kovatch is the founding Associate Dean for Scientific Computing at the Icahn School of Medicine at Mount Sinai. She joined in October 2011 and established a scalable and sustainable high-performance computing infrastructure, emphasizing a collaborative approach partnering computational experts with Sinai's scientists to tackle complex scientific questions to better diagnose and treat disease.
She initiated a graduate curriculum in Scientific Computing and Biomedical Informatics. Research and development activities include improving neurosurgical virtual reality simulation environments, cloud computing and markets, and a statewide consortium to accelerate data-intensive science. She also manages teams with significant data-rich research and clinical resources: the Mount Sinai Data Warehouse and the Research Information Technology groups.
Prior to joining Mount Sinai, Kovatch built and led the $75M National Institute for Computational Sciences of the University of Tennessee, Knoxville, located at Oak Ridge National Laboratory. She deployed the world's third-fastest machine in November 2009, a 1.17 petaflop Cray XT5 for the National Science Foundation and published research on wide area parallel file systems and scheduling.
Philip J. Landrigan, MD, MScDean for Global Health and Ethel H. Wise Professor and Chair of the Department of Preventive Medicine of Icahn School of Medicine at Mount Sinai
Philip Landrigan's research on the effects of lead poisoning in children led the U.S. government to mandate removal of lead from gasoline and paint. His leadership of a National Academy of Sciences Committee on pesticides generated widespread understanding that children are uniquely vulnerable to toxic chemicals and led to passage of the Food Quality Protection Act, the federal law on pesticides. Dr. Landrigan has consulted extensively to the World Health Organization. He has been centrally involved in the medical and epidemiologic studies that followed the destruction of the World Trade Center on September 11, 2001.
Dr. Landrigan served from 1996 to 2005 in the Medical Corps of the United States Naval Reserve. He retired in 2005 at the rank of Captain. He served in Korea, Ghana and Senegal. He was awarded the Navy Commendation Medal (3 awards), the National Defense Service Medal, and the Secretary of Defense Medal for Outstanding Public Service. He serves currently as Surgeon General of the New York Naval Militia, the maritime component of New York's National Guard.
W. David LeeChief Executive Officer, Lumicell, Inc.
W. David Lee is the CEO of Lumicell, Inc., a leader in developing an intraoperative imaging system that gives surgeons real-time visual feedback of residual
cancer in the tumor bed. Lumicell imaging technology was developed at MIT in a project sponsored MIT Koch Institute for Integrative Cancer Research where Mr. Lee worked as the interface of technologists and clinicians.
Previously, Mr. Lee was the founding CEO of T2 Biosystems, Inc., a platform diagnostics company, and he is a co-founder along with prominent faculty from MIT and MGH. He founded Caveo Technology in 1999, and though his leadership as CEO, Caveo developed proprietary motion-based technology for security, entertainment, and location awareness. He sold the company to a private investor in 2004.
In the mid-1990's he consulted for Analog Devices in the development of MEMS technology and Carrier Corporation in improvement of the world-wide manufacturing operations. Starting in 2005, he served for several years as the Director of Engineering for Analog Devices Micromachined Products Division. This followed 25 years at Arthur D. Little were he led the development of aerospace, electronic, cryogenic, biomedical, consumer, and energy product as well as technology for home appliances. In addition to leading numerous developments, Mr. Lee was Senior Vice President of Arthur D. Little, Inc. and managing director of the Technology and Product Development business. Mr. Lee also drove the ADL investments leading to the successful development and licensing of lithium battery technology, fuel cell reformer, the Scroll air conditioning compressor, heading sensor, and automated fryer, among others.
Mr. Lee has served as a board member for the Kryptonite Corporation and Water
Resources Inc. He received his BS and MS in Mechanical Engineering with honors
from the Massachusetts Institute of Technology and completed the Harvard Business School Advanced Management Program.
John Lepore, MDVice President and Head, Heart Failure Discovery Performance Unit, GlaxoSmithKline
John Lepore is the Vice President and Head of the Heart Failure Discovery Performance Unit at GlaxoSmithKlein (GSK). In this role, Dr. Lepore leads a multidisciplinary group of scientists and physicians responsible for discovery and early clinical development of novel therapies for heart failure and related cardiovascular disorders. In addition, Dr. Lepore is the global Medicine Development Leader for GSK's HIF-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. Dr. Lepore completed clinical training in internal medicine and cardiology at Massachusetts General Hospital where he also served as Chief Medical Resident and studied the role of novel pulmonary vasodilator therapies in patients with pulmonary hypertension. He completed post-doctoral training in the laboratory of Jeffrey Leiden and subsequently joined the faculty of the Cardiovascular Medicine Division of the University of Pennsylvania where his laboratory studied the transcriptional regulation of cardiovascular development and function. He joined GSK in 2006 and was previously head of Clinical Pharmacology and Discovery Medicine in the Cardiovascular and Urogenital Center of Excellence in Drug Discovery.
Gary S. May, PhDProfessor and Dean, Georgia Institute of Technology
Gary S. May is the Dean of the College of Engineering and Professor of Electrical and Computer Engineering at the Georgia Institute of Technology. In that capacity, Dr. May serves as the Chief Academic Officer of the college and provides leadership to over 400 faculty members and to more than 13,000 students. The College of Engineering at Georgia Tech is the largest producer of engineering graduates in the United States. In the most recent rankings by U.S. News & World Report, Georgia Tech's engineering program ranked fifth.
Prior to his current appointment, Dr. May was the Steve W. Chaddick School Chair of the School of Electrical and Computer Engineering at Georgia Tech. At the conclusion of his leadership in 2011, graduate programs in electrical engineering and computer engineering each ranked sixth, the computer engineering undergraduate program also ranked sixth, and the electrical engineering undergraduate program ranked fifth. All of these rankings represented the highest in the history of the School up to that point.
Gavin McIntyreCo-founder and Chief Scientist, Ecovative Design
Since founding Evocative Design in 2007, Gavin has led all material and biological process development in the company's strides to replace plastics and foams. He co-invented Ecovative's patent-pending technology that uses a fungal mycelium to transform agricultural waste into strong biological composite materials. These materials are 100% compostable, and made with a fraction of the energy of conventional plastics. He has served as the principle investigator on grants received from the US EPA, the USDA, the NSF, and the New York State Energy Research and Development Authority. Gavin currently serves on the board of the NYS Pollution Prevention Institute, a subset of the Department of Environmental Conservation, and the NYS Center for Automation Technology and Systems. Gavin received a dual B.S. In Mechanical Engineering and Product Design from Rensselaer Polytechnic Institute, and has a number of utility patents to his name.
Charles Mobbs, PhDProfessor of Neuroscience, Endocrinology, and Geriatrics Icahn School of Medicine at Mount Sinai
Charles Mobbs is Professor of Neuroscience, Endocrinology, and Geriatrics. He earned his Bachelor of Science degree in Life Sciences from Massachusetts Institute of Technology, his Ph.D. in Cellular and Molecular Science from the University of Southern California with Dr. Caleb Finch, and carried out his post-doctoral research with Dr. Donald Pfaff at Rockefeller University. He was promoted to Assistant Professor at Rockefeller, then came to Mount Sinai in 1992. Recent awards include 2010 "Outstanding Mentorship" at Mount Sinai, the Glenn Award for Basic Research in Aging in 2012, and Delegate, China Strategic Alliance of Prevention and Treatment Technology for Diabetes, Consortium of Chinese Central Government, University, Research, Institute, and Government in 2013. His research, which focuses on neuroendocrine and metabolic mechanisms of aging and age-related diseases, is described in more detail on the PBS documentary which can be seen at http://tinyurl.com/mobbsonPBS and in a recent presentation at http://tinyurl.com/MobbsatUTSA.
Rear Admiral Scott P. MooreDeputy Commander, Naval Special Warfare Command, United States Navy
Rear Admiral Scott P. Moore is from Colorado Springs, Colo., and graduated from the United States Air Force Academy, Class of 1983, with a Bachelor of Science degree. Upon graduation, he received an inter-service commission, attended Basic Underwater Demolition/SEAL (BUD/S) training in Coronado, Calif., and graduated from BUD/S Class 126 in January 1984. Moore has commanded at every level of Naval Special Warfare; from platoon, assault squadron, and SEAL Team, to commander, Naval Special Warfare Development Group. Additionally, he commanded a Joint Special Operations Task Force in Afghanistan for several years. He has also served in numerous staff positions including the SEAL officer detailer; maritime operations officer at Special Operations Command Europe; director, Counter Terrorism Division, National Security Council; deputy director for Special Operations and Counterterrorism, Joint Staff; and as deputy for operations, Office of the Defense Representative to Pakistan. Currently, he is assigned as the deputy commander, Naval Special Warfare Command. He is a graduate (with distinction) of the Senior Naval War College, earning a master's in National Security Affairs.
Richard R. Nelson, PhDGeorge Blumenthal Professor of International and Public Affairs, Business, and Law, Emeritus, at Columbia University
Richard R. Nelson is an economist by formal training, but his interests and research have spanned a wide range of subjects and disciplines. Over his career he has taught at Oberlin College, Carnegie Mellon University, Yale University, and Columbia University. He now heads the program on Science, Technology, and Global Development, at the Columbia Earth Institute, and is George Blumenthal Professor of International and Public Affairs, Business, and Law, Emeritus, at Columbia University. He has served as research economist and analyst at the Rand Corporation, and at the President's Council of Economic Advisors. He was director of the Institute for Social and Policy Studies at Yale University, and has directed Columbia's Public Policy Doctoral Consortium.
His central interests have been in long-run economic change. Much of his research has been directed toward understanding technological change, how economic institutions and public policies influence the evolution of technology, and how technological change in turn induces institutional and economic change more broadly.
Michael Nielsen, PhDAuthor, Reinventing Discovery: The New Era of Networked Science
Michael Nielsen leads dual lives as a working scientist and as a writer and speaker advocating for a more open scientific culture. His career began in quantum computing, a field he helped pioneer in the 1990s and 2000s. He co-authored the standard text on quantum computing--now one of the ten most cited books in the history of physics--and wrote more than 50 scientific papers. His work on quantum teleportation was recognized in Science Magazine's Top Ten Breakthroughs of 1998. Dr. Nielson was educated at the University of Queensland, and as a Fulbright Scholar at the University of New Mexico. He worked as the Tolman Prize Fellow at Caltech, as Foundation Professor of Quantum Information Science at the University of Queensland, and a Senior Faculty Member at Perimeter Institute for Theoretical Physics. In 2008, he left his tenured position to work fulltime on open science. His advocacy work has appeared in Nature, at TED.com, and in the Wall Street Journal. In 2013 he is on sabbatical writing a book about artificial neural networks.
Rosalyn Taylor O'NealePrincipal Consultant, Cook Ross, Inc.
From the segregated South, across five continents, this African American woman has filled her life with interesting people and difficult subjects. Rosalyn Taylor O'Neale, Principal Consultant at Cook Ross, has over 25 years as a global diversity and inclusion thought leader and practitioner. Most recently she was Vice President, Chief Diversity & Inclusion Officer for Campbell Soup Company where she successfully lead Campbell's efforts to develop and implement their global diversity and inclusion strategic plan.
Prior to Campbell Soup, she was Executive Vice President Diversity Initiatives for MTV Network and CEO of Barnes O'Neale & Associates. An Internationally recognized speaker, Rosalyn has been quoted in Black Enterprise Magazine, Diversity Journal and Harvard Business Review. She was named one of the Most Influential Blacks in Corporate America by Savoy Magazine and Top Executives In Diversity in Black Enterprise Magazine. O'Neale is the author of "Seven Keys to Success: Unlocking The Passion For Diversity." She has a Masters in Social Work from the University of Louisville and has completed post graduate work in Human and Organization Systems.
Alice ParkStaff Writer, TIME
Alice Park is a staff writer at TIME. Since 1993, she has reported on the breaking frontiers of health and medicine in articles covering issues such as AIDS, anxiety, and Alzheimer's disease. Park has received two CASE media fellowships — the first in 2000 to Harvard Medical School, where she designed a program focused on the latest understanding of AIDS, and the second in 2003 to UCLA's Medical School, where she researched the growing number of clinical applications of genomic research. In addition, Park's work has been recognized with awards of excellence from the National Arthritis Foundation as well as the National Headache Foundation.
Vivek V. Patil, MDChief Resident, Department of Radiology, Icahn School of Medicine at Mount Sinai
Vivek V. Patil, MD, is currently Chief Resident in the Department of Radiology at Icahn School of Medicine at Mount Sinai. He is a graduate of The George Washington University and plans to pursue a career in interventional radiology. Dr. Patil's research interests include information technology and, more specifically, mobile application development. He is a co-founder of Radical Radiologist, a mobile social gaming platform for radiology education.
Matthew PendletonGraduate Student, Icahn School of Medicine at Mount Sinai
Matthew Pendleton is a graduate student in structural/chemical biology and molecular design under the direction of Professors Ali Bashir and Thomas Moran. His primary research interests lie in the mathematics of the relationship between biological optimization as it is generated in the language of DNA and enacted in the language of structural molecular recognition, particularly in the context of adaptive immune responses. Before coming to the Icahn School of Medicine at Mount Sinai, Mr. Pendleton was a genome engineer in the VelocImmune Next group at Regeneron Pharmaceuticals. At Regeneron, he created mouse lines with various humanized immune receptors involved in quality control during B-cell maturation.
Lauren PetersPhD Candidate, Icahn School of Medicine at Mount Sinai
Lauren Peters is a PhD Candidate in Immunology in the Dudley Laboratory at the Icahn School of Medicine at Mount Sinai. Her research is focused on elucidating the causal drivers of Inflammatory Bowel Disease (IBD), which is comprised of Crohn's disease (CD) and ulcerative colitis (UC), through the study of the functional outcome of genetic predisposition. There are at least 163 susceptibility loci, as defined by Genome Wide Association Studies (GWAS), associated with IBD. These loci span the majority of the pathways involved in maintenance of gut homeostasis. Ms. Peters' goal is to map these SNPs to specific loci and determine their relative organization and hierarchy. Through in silico perturbations of these networks, predicted outcomes will be compared with disease model validation to develop empirical networks to gain a better understanding of the master regulators and define core control hubs operating in innate and adaptive mucosal immunity as well as crosstalk with the gut epithelium and stroma. This will enable definition of the clinically heterogeneous and multifactoral IBD into molecular subsets to help guide therapeutic target and biomarker discovery as well as provide a framework for matching patient genetic predispositions with optimal clinical treatment.
Madhumitha RengasamyPhD student, Icahn School of Medicine at Mount Sinai
Madhumitha Rengasamy completed her undergraduate degree in Microbiology, Chemistry and Zoology at St. Joseph's College in Bangalore, India. Interested in pursuing research work in the field of cancer biology, she joined the National University of Singapore as a Research Scholar in 2007 where she worked on gene therapy of glioblastoma for the next two years. She joined the PhD program at the Icahn School of Medicine at Mount Sinai in Fall 2010. She is currently doing her doctoral research on the epigenetic regulation of breast cancer in Dr. Martin Walsh's laboratory.
Eric Rose, MDProfessor of Health Evidence and Policy, Cardiothoracic Surgery, Surgery and Medicine, Icahn School of Medicine at Mount Sinai
Eric Rose, MD, is an academic physician and entrepreneur with interests in drug discovery, biodefense, clinical evaluative research, and health policy. Since 2007, he has been the Executive Vice President for Life Sciences at MacAndrews & Forbes and CEO of Siga Technologies, Inc., a developer of anti-viral drug directed at potential agents of bioterror. From 2001 through 2007, he served on the National Biodefense Scientific Board which advises the US Health and Human Services Secretary on biodefense, influenza, and emerging diseases. From 2008 through 2012, he chaired the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he held a distinguished professorship. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. A pioneer in heart transplantation in children, he performed the first successful pediatric heart transplant in 1984.
Bhaven N. Sampat, PhDAssociate Professor, Department of Health Policy and Management Columbia University's Mailman School of Public Health
Bhaven N. Sampat is an Associate Professor in the Department of Health Policy and Management at Columbia University. He also holds a courtesy affiliation with Columbia Law School and the School of International and Public Affairs, and is a Research Associate of the National Bureau of Economic Research.
Dr. Sampat is an economist by training, interested in issues at the intersection of health policy and innovation policy. His current work examines brand-generic completion in pharmaceuticals, the impact of drug patents on innovation and access to medicines in the developing countries, the political economy of the NIH, and the role of serendipity in biomedical discovery. He has also written extensively on the effects of university patenting and the Bayh-Dole Act on academic medicine, and on patent quality issues in the U.S., and continues to be actively involved in policy debates related to these issues. He has published in economics, law, business, health policy, medical and life science journals.
Nirav R. Shah, MD, MPHCommissioner of Health, New York State
Nirav R. Shah is the 15th New York State Commissioner of Health. He heads one of the nation's leading public health agencies with a budget of more than $50 billion, and administers the state's public health insurance programs, which cover 5 million New Yorkers. The Department also regulates hospitals and other health care facilities, conducts research in a premier biomedical laboratory, and supports public health and prevention initiatives.
A native of Buffalo, Dr. Shah is board-certified in Internal Medicine and is an honors graduate of Harvard College and Yale School of Medicine. He was a Robert Wood Johnson Clinical Scholar at UCLA and a National Research Service Award Fellow at New York University. Before becoming Commissioner, he was Attending Physician at Bellevue Hospital Center in Manhattan, Associate Investigator at the Geisinger Center for Health Research in central Pennsylvania, and Assistant Professor of Medicine in the Section of Value and Comparative Effectiveness at NYU Langone Medical Center.
Peter K. Smith, MDProfessor and Chief of Cardiothoracic Surgery, Duke University
Peter K. Smith is Professor and Chief of Cardiothoracic Surgery at Duke University. Dr. Smith is a graduate of Princeton University (Phi Beta Kappa), Duke Medical School (AOA), and of the Duke General Surgery and Thoracic Surgery residencies. He has received the AHA Clinician Scientist Award, an NIH Research Career Development Award, and is currently the Duke PI in the NHLBI Cardiac Surgery Research Network. He has authored or co-authored 140 peer-reviewed publications. He has a long-standing interest in clinical databases and has managed the Duke Cardiac Surgery clinical database since 1987, collaborating with the STS National Cardiac Database since its inception. His most recent work has focused on comparative effectiveness of PCI and CABG and he is the surgeon member of the AHA/ACC Appropriateness Criteria writing committee and Vice-Chair of the ACC/AHA CABG Guideline Committee. He has pioneered the use of clinical databases to improve the accuracy of the Medicare Physician Fee Schedule as the Thoracic Surgery member of the AMA Relative Value Update Committee (RUC). For this work, he received the Distinguished Service Award of the Society of Thoracic Surgeons in 2006.
Geoffrey W. Smith, JDDirector of the Center for Technology, Innovation, and Entrepreneurship (C-TIE) at Icahn School of Medicine at Mount Sinai
Geoffrey W. Smith is the founding Director of the Center for Technology, Innovation, and Entrepreneurship (C-TIE) at Icahn School of Medicine at Mount Sinai. He is also a Professor in the Department of Health Evidence and Policy at Icahn School of Medicine.
Smith is a co-founder and General Partner of Ascent Biomedical Ventures, a venture capital firm focused on early-stage life sciences investments. He has been an active founder, manager, and investor in technology-based companies since 1995. He currently serves on the Board of Directors of Azevan Pharmaceuticals, Anterios, BackBeat Medical, Biomerix, Caliber Therapeutics, Coferon, TargAnox, and Vivasure Medical and is a Board Observer for Cara Therapeutics.
Smith is also a Visiting Scholar at Rockefeller University where he founded and directs the University's Science & Economics Program and is an adjunct faculty member at the RU Center for Clinical and Translational Science.
He received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.
John Stamatoyannopoulos, MDAssociate Professor of Genome Sciences and Medicine, University of Washington School of Medicine
John Stamatoyannopoulos, MD, is Associate Professor of Genome Sciences and Medicine at the University of Washington School of Medicine. Dr. Stamatoyannopoulos is also Director of the UW ENCODE Center, the Northwest Epigenome Center, and the UW High-Throughput Genomics Center. He holds degrees in Biology, Symbolic Systems, and Classics, from Stanford University, and an M.D. from the University of Washington. He trained in Internal Medicine at Brigham and Women's Hospital, Harvard Medical School, and Oncology and Hematology at the Dana Farber Cancer Institute and Massachusetts General Hospital.
Dr. Stamatoyannopoulos is one of the leaders of the ENCODE Project and the Roadmap Epigenomics Project, major 'team science' efforts which are transforming our understanding of human genome function and its role in development and disease. His lab focuses on understanding the regulatory programs of complex genomes through the application of genome-scale molecular and computational technologies. Major ongoing efforts are to: delineate the cis-regulatory architecture of the human and mouse genomes; map and analyze transcription factor regulatory networks; determine the functional consequences of disease-associated non-coding variation in regulatory DNA; and develop transformative technologies for analysis of regulatory DNA and genomic control mechanisms.
Joe TorreExecutive Vice-President, Baseball Operations, Major League Baseball
Joe Torre is Major League Baseball's Executive Vice President for Baseball Operations, a position he has held since February 2011. In this capacity, he oversees areas that include Major League Operations, On-Field Operations, On-Field Discipline, and Umpiring. He serves as the Office of the Commissioner's primary liaison to the general managers and field managers of the 30 Major League Clubs regarding all baseball and on-field matters. Since December 2009, he has served on the Commissioner's Special Committee for On-Field Matters.
Torre is also Chairman of the Joe Torre Safe At Home Foundation, which he and his wife, Ali, launched in 2002. In 2010, Torre was appointed by President Barack Obama to serve on the National Advisory Committee on Violence Against Women. Since October 2011, he has served as Co-Chair of the U.S. Justice Department?s National Task Force on Children Exposed to Violence.
In Fall 2010, Torre concluded his third and final season as Manager of the Los Angeles Dodgers, who he led to the National League Championship Series in 2008 and 2009. Previously, he spent 12 seasons as Manager of the New York Yankees (1996-2007), guiding them to the Playoffs every year, including six World Series appearances and four World Championships (1996, 1998, 1999, and 2000).
Torre made his managerial debut with the New York Mets on May 31, 1977, becoming the first player-manager in the majors since 1959. He managed the Mets until 1981 and the Atlanta Braves from 1982-1984. After spending nearly six seasons as a television broadcaster for the California Angels, he managed the St. Louis Cardinals from 1990-1995.
Torre ranks fifth in all-time managerial wins, with 2,326. The Associated Press named him Manager of the Year in 1982 and 1998. In 1996 and 1998, the Baseball Writers Association of America named him American League Manager of the Year and, in 1996, The Sporting News named him Sportsman of the Year. He won ESPN's ESPY Award for Best Manager/Coach of the Year in 1997, 1999, 2000 and 2001.
During his 17-year playing career (first/third baseman, catcher) with the Milwaukee/Atlanta Braves, the St. Louis Cardinals and the New York Mets, Torre compiled a lifetime .297 batting average, had 2,342 hits, 252 home runs and 1,185 RBI's, and hit over .300 five times. He was a nine-time All-Star and the National League's 1971 Most Valuable Player, batting .363 with 230 hits, 24 home runs and a league-leading 137 RBIs.
The Joe Torre Safe At Home Foundation's mission is to develop educational programs that will end the cycle of domestic violence and save lives. Since its inception, the Foundation has educated thousands of students, parents, teachers and school faculty about the devastating effects of domestic violence.
Currently reaching children in eight schools and two community centers in metropolitan New York City and one school in Los Angeles, Margaret's Place, a tribute to Joe's mother, provides middle and high school students with a "safe room," in which to talk about violence-related issues with each other and a professional counselor trained in domestic violence intervention and prevention.
Torre is the co-author of three books: The Yankee Years (Doubleday 2009), Chasing the Dream: My Lifelong Journey to the World Series (Bantam 1997, 1998) and Joe Torre's Ground Rules for Winners: 12 Keys to Managing Team Players, Tough Bosses, Setbacks and Success (Hyperion 1999).
Torre was born on July 18, 1940 in Brooklyn, NY. He, Ali and their daughter, Andrea, live in Beverly Hills, CA. His three adult children are Michael, Cristina, and Lauren.
Neha UppalPhD Student, Icahn School of Medicine at Mount Sinai
Neha Uppal graduated from Tufts University in 2009 with a degree in Child Development and Biomedical Engineering with the hope of doing research focusing on children with mental illnesses. She began graduate school at the Icahn School of Medicine at Mount Sinai later that year and recently completed her doctoral research on the neuropathology of autism in Patrick Hof's laboratory. Ms. Uppal will be continuing her work on children with autism as a postdoctoral fellow at Albert Einstein in 2014.
Matthew VanBesienExecutive Director, New York Philharmonic
Matthew VanBesien is the Executive Director of the New York Philharmonic. Prior to the Philharmonic, VanBesien served as managing director of the Melbourne Symphony Orchestra (2010-12). This followed positions at the Houston Symphony as executive director and chief executive officer (2005-10) and general manager (2003-05). He is a member of the Board of Overseers for The Curtis Institute of Music in Philadelphia and a former Board Director for Symphony Services International (formerly Symphony Australia).
A native of St. Louis, Missouri, VanBesien earned a bachelor of music degree in French horn performance from Indiana University. As a professional musician, he was second French horn of the Louisiana Philharmonic Orchestra in New Orleans from 1992 to 2000. In the 2001-02 season, he completed the League of American Orchestra's Orchestra Management Fellowship Program, a highly selective, year-long management training program designed to develop orchestral leadership talent. During this fellowship he worked at the Aspen Music Festival, Los Angeles Chamber Orchestra, Phoenix Symphony, and Pittsburgh Symphony Orchestra. VanBesien is married to Rosanne Jowitt, a geoscientist.
Deepak Vashishth, PhDDirector, Center for Biotechnology and Interdisciplinary Studies Professor of Biomedical Engineering, Rensselaer Polytechnic Institute
Deepak Vashishth, PhD, earned his Bachelor of Engineering with honors from Malaviya National Institute of Technology in India, Master of Science from West Virginia University, and PhD from the University of London. He conducted post-doctoral research in the Department of Orthopaedic Surgery at Henry Ford Hospital before joining Rensselaer in 1999. He is currently the Director Center for Biotechnology and Interdisciplinary Studies and Professor of Biomedical Engineering at Rensselaer. His research interests are biomolecular science and engineering of extracellular matrix with particular emphasis on diagnosis and treatment of osteoporosis and bone tissue engineering. Professor Vashishth has published more than 200 peer-reviewed journal publications and conference proceedings. His work, presented in the form of more than 100 invited and contributed lectures, has been cited as a New Hope for Osteoporosis Patients. Dr. Vashishth is a fellow of the AIMBE and an editorial board member of Bone and JMBBM. He serves as a member of the NIH section on Skeletal Biology and Skeletal Regeneration. He is a member of the Biomedical Engineering Society, American Society of Bone and Mineral Research, and the Orthopaedic Research Society.
David ZhangPhD Student, Icahn School of Medicine at Mount Sinai
David Zhang is a sixth year MD/PhD candidate at the Icahn School of Medicine at Mount Sinai. He hails from the genetics and genomic sciences multidisciplinary training area, and is passionate about human genetics and genomics. Mr. Zhang is completing his thesis work in the laboratory of Dr. Scott Friedman, and studies the transcriptional regulation of myofibroblast activation in chronic liver disease.